Trials / Unknown
UnknownNCT03902067
UC-MSC Transplantation for Left Ventricular Dysfunction After AMI
Safety and Efficacy Evaluation of Umbilical Cord Mesenchymal Stem Cells Transcatheter Transplantation to Treat Left Ventricular Dysfunction After Acute Myocardial Infarction
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Shanghai Life Science & Technology · Industry
- Sex
- All
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
A pilot study to evaluate the safety and feasibility of umbilical cord mesenchymal stem cells in the treatment of acute myocardial infarction by catheter transplantation
Detailed description
In this study, 40 patients with cardiac insufficiency after acute myocardial infarction were selected and randomly divided into umbilical cord MSCs transplantation treatment group and non-intervention control group to preliminarily observe the safety and effectiveness of MSCs cell transplantation treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | UC-MSC | 0.25ml Shanghai Life UC-MSC injection is resuspended into 10ml of cell suspension and slowly infused into infarct-related blood vessels through an administration catheter in 2 minutes, and the number of cells transplanted each time is 5x10(6) cells. The UC-MSC products are manufactured by Shanghai Life with viability\>80%, and endotoxin\<0.1 EU， at the concentration of 2x10(7) cells/ml. |
| BIOLOGICAL | Control Group | Routine treatment without catheter infusion |
Timeline
- Start date
- 2024-12-01
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
- First posted
- 2019-04-03
- Last updated
- 2024-04-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03902067. Inclusion in this directory is not an endorsement.